Phaseline

Targets › UBA3

UBA3 (NEDD8-activating enzyme E1 catalytic subunit): drug programs, companies and trials

5 programs from 5 companies in 6 trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Nov 2026.

Catalytic subunit of the dimeric UBA3-NAE1 E1 enzyme. E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Down-regulates steroid receptor activity. (UniProt, Q8TBC4)

Open in Phaseline: the race on UBA3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PETHEMA FoundationPevonedistat
NEDD8 activating enzyme inhibitor
UBA3, NAE1Phase 3Leukemia, Myeloid, Acute–
National Cancer Institute (NCI)Pevonedistat
NEDD8 activating enzyme inhibitor
UBA3, NAE1Phase 2Metastatic Lung Non-Small Cell Squamous Carcinoma; Metastatic CholangiocarcinomaMar 2027
City of Hope Medical CenterPevonedistat
NEDD8 activating enzyme inhibitor
UBA3, NAE1Phase 1B-Cell Prolymphocytic LeukemiaNov 2026
University of Southern CaliforniaPevonedistat
NEDD8 activating enzyme inhibitor
UBA3, NAE1Phase 1Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeDec 2026
M.D. Anderson Cancer CenterPevonedistat
NEDD8 activating enzyme inhibitor
UBA3, NAE1Phase 1Acute Myeloid LeukemiaJan 2027

Conditions

B-Cell Prolymphocytic Leukemia (1) Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (1) Metastatic Lung Non-Small Cell Squamous Carcinoma (1) Metastatic Cholangiocarcinoma (1) Acute Myeloid Leukemia (1) Leukemia, Myeloid, Acute (1)

Modalities

small molecule (4), mixed (1)

Companies

City of Hope Medical Center (1) University of Southern California (1) National Cancer Institute (NCI) (1) M.D. Anderson Cancer Center (1) PETHEMA Foundation (1)

Related targets

NAE1 (5)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.